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The gold standard for tile diagnosis of acute poisoning is toxicological analysis. Because 
information on the incorporated toxic substance provided by the patient or his relatives is 
known from experience to be unreliable in about 4097 of all intoxications, a screening 
procedure that covers most relevant drugs and toxicants is required rather than an analytical 
procedure optimized for the identification of a single class of substances. The special task for 
a general unknown screening procedure is to identify a toxic substance among endogenous 
or food-derived substances as well as environmental toxicants in a biological matrix on an 
emergency basis. Because the unknown toxic substance may vary considerably in its 
physicochemical properties and its concentration range, a universally applicable screening 
procedure is required. Although gas chromatography-mass spectrometry has been used for 
three decades, it still offers many unique advantages in terms of sensitivity, specificity, 
reliability, and coverage of a large number of toxic substances. Because the procedure has to 
be kept as simple and as short as possible, compromises have to be made with respect o 
extraction, derivatization, and mass-spectral techniques. The specimen of choice for a general 
unknown screening is-- i f  available--urine. The standard mode of ionization is electron 
impact. The identification of unknown substances is highly challenging because, in our 
experience, previously unknown metabolites may be detected rather frequently in acute 
poisoning. Although an atttomated mass spectra library search considerably facilitates the 
identification process, expert knowledge on the identification of substances not included in 
the library as well as knowledge in clinical toxicology and metabolism is indispensable. 
(J Am Soc Mass Spectrom 1995, 6, 995-1003) 
I 
n Germany, about 4000 to 5000 patients die from 
acute poisoning each year, which is about half the 
number of individuals that die in traffic accidents. 
An estimated 200,000 patients per year are treated for 
acute poisoning in emergency wards [1, 2]. Table 1 
gives an overview of the most frequently ingested 
drugs in suicidal intoxications. In Germany, about two 
thirds of acute poisonings are due to drug overdose. 
More than one drug is ingested in 46% of all cases of 
drug overdose. About two thirds of the intoxications 
are due to suicidal drug ingestion. Ethanol is involved 
in about 40% of all acute suicidal poisonings [3, 4]. 
The diagnosis of acute poisoning is based on the 
history, clinical symptomatology (which, however, is 
generally rather unspecific), standard laboratory tests, 
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and toxicological analysis. There is general agreement 
that emergency toxicological analysis is the gold stan- 
dard for the diagnosis of acute poisoning [2, 5]. Unfor- 
tunately, only few intoxications are characterized by 
highly specific symptoms that allow diagnosis primar- 
ily on the basis of the clinical findings [4]. It has been 
demonstrated empirically that information on the in- 
gested drug or toxicant obtained from patients or their 
relatives is incomplete or incorrect in about 40°73 of all 
poisonings [2]. Therefore, an emergency analytical pro- 
cedure should not only aim at the most probable 
ingested toxic substance, but also should include all 
of the most commonly ingested drugs or toxicants. 
A general unknown screening procedure that covers 
as many drugs and toxicants as possible and that 
has a high reliability, sensitivity, and specificity is re- 
quired [5]. 
A general unknown screening is a completely dif- 
ferent task in comparison to identification and quanti- 
tation of a given substance in a biological matrix. In 
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Table 1. Frequency, prescription, and elimination characteristics of drugs  in drug overdose in 
patients admitted to tile medical intensive care unit of the Universit~itsklinikum Rudolf Virchow, 
Berlin, in 1993 ( n = 323 patients) 
Under Extensive 
Frequency prescription hepatic Renal 
Drug (%) in Germany metabolism elimination 
Benzodiazepines 39 + ++ + 
Doxylamine, diphenhydramine 9 - ++ + 
Tricyclic antidepressants 8 + +++ + 
Neurolept ics 6 + +++ + 
Acetaminophen 6 - + ++ 
Aspir in  2 - + +++ 
Barbiturates 2 + + ++ 
Betablockers 1 + + to ++ + 
Ant ia r rhythmics  0.8 + ++ + 
Others 25.2 
the latter case, a highly optimized approach that uses 
sophisticated equipment may be used to detect just a 
single compound or a well-defined class of com- 
pounds. If the objective is to identify an unknown toxic 
substance that is responsible for acute poisoning under 
emergency conditions, the demands on the analytical 
procedure are completely different. 
The analytical approach as to cover as many rele- 
vant toxic substances as possible. The toxic substance 
has to be distinguished from endogenous or food- 
related substances and environmental toxicants in the 
biological matrix, which may be subject to consider- 
able interindividual variation. Because invasive treat- 
ment such as hemoperfusion, plasmapheresis, or hy- 
perventilation may be the consequence of the results of 
a general unknown screening, the analytical toxicolo- 
gist has a great responsibility for the reliability of his 
findings. Furthermore, the analytical procedure has to 
be tested in a large number of acute poisonings with 
different substances under routine conditions. 
A major requirement for general unknown screen- 
ing is its universal applicability to most classes of toxic 
substances. However, it is not necessary to demand 
inclusion of some special substances like ethanol, 
volatiles, digitalis glycosides, or heavy metals in this 
universal procedure. In practice, detection of these 
substances does not pose a major problem because 
ethanol, digitoxin, or digoxin determination is rou- 
tinely performed by most hospital laboratories, 
whereas heavy metal toxicity is typically so specific in 
its symptom pattern that the diagnosis is hard to miss. 
Volatiles, which typically cause a specific odor of the 
exhaled air, may be identified by a modified general 
unknown screening by gas chromatography-mass 
spectrometry (GC-MS) by using lower temperatures 
for the gas chromatography (GC) procedure [6]. 
GC-MS offers unique advantages over other com- 
peting analytical methods for a general unknown 
screening [3-5, 7-12]. It has been in use for three 
decades and is highly specific, highly sensitive, univer- 
sally applicable, covers a large number of relevant 
toxic substances, and requires relatively little time for 
an emergency analysis. However, for reasons of cost, it 
is not possible to provide a 24-hour service for a 
general unknown screening by GC-MS in all areas of a 
country but only in special centers mainly located in 
urban regions [2]. A rather long transportation time of 
samples to a toxicological laboratory may be a limiting 
factor in cases of serious poisoning. If a GC-MS facility 
is not available, other analytical methods, especially 
those available in many hospital laboratories, may be 
considered as a compromise for a general unknown 
screening. Evaluation of these methods has been en- 
forced and sponsored by a German research program 
of the Deutsche Forschungsgemeinschaft [2, 6, 13-15]. 
Analytical methods that compete with a GC-MS 
approach to a general unknown screening are combi- 
nations of immunoassays, which are commercially 
available for many classes of drugs like benzodi- 
azepines, opiates, barbiturates, acetaminophen, tri- 
cyclic antidepressants, theophylline, and anticonvul- 
sive drugs [1]. These immunoassays are frequently 
available in hospital laboratories [1]. A major disad- 
vantage of immunoassays i the limited number of 
drugs that are covered by a combination of the assays. 
It is desirable that positive results of an immunoassay 
be confirmed by an independent analytical method [1]. 
The same is true for general unknown screening proce- 
dures that use thin-layer chromatography (TLC), gas 
chromatography, o r high-performance liquid chro- 
matography (HPLC) [1, 16, 17]. The specificity of the 
latter method may be improved considerably by the 
use of a diode array detector. However, all these meth- 
ods lack specificity and universal applicability com- 
pared to GC-MS [1]. This disadvantage may be over- 
come partly by using different solvent and detection 
systems in TLC or different GC or HPLC columns 
[2, 6, 12, 13, 16, 17]. 
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Types of Samples 
In acute poisoning, gastric content or gastric lavage 
fluid, blood, plasma, serum, and/or  urine may be 
analyzed. Analysis of gastric content or gastric lavage 
fluid will provide information on an ingested drug 
that has not yet undergone complete absorption. De- 
tection of toxicants, drugs, or their metabolites in urine 
will provide information on substances that have un- 
dergone at least partial hepatic metabolism and have 
already passed through the body [5]. After complete 
absorption of a toxic substance, the quantification of a 
toxicant, drug, or their metabolites in blood, plasma, or 
serum allows an estimation of the severity of an acute 
intoxication (see Table 2). 
For practical purposes and restriction of costs, a 
screening procedure should focus primarily on urine, 
which contains higher concentrations of most drugs 
and toxicants than blood, serum, or plasma. However, 
it has to be kept in mind that many substances un- 
dergo nearly complete metabolism, which means that 
in overdose with substances ubjected to extensive 
hepatic metabolism, only metabolites but not the par- 
ent compound may be detectable in urine. Because the 
dose range in drug or toxicant overdose is typically 
several milligrams to grams, sensitivity is not a special 
problem in urine analysis. Urine concentrations typi- 
cally vary between the nanogram to microgram per 
milliliter range. Unexpectedly high concentrations of a 
toxic substance and its metabolites in urine may pose 
some problems with GC column overload and mem- 
ory effects in the ion source of the mass spectrometer. 
With few exceptions, most drug or toxicant metabo- 
lites have a considerably higher polarity than their 
parent compounds, which may render the extraction 
yield achieved with organic solvents rather poor, espe- 
cially if conjugates are formed. This problem can 
be overcome by conjugate cleavage by hydrochloric 
acid hydrolysis or enzymatic hydrolysis with 
glucuronidase-sulfatase [5]. For an emergency proce- 
dure, hydrochloric acid hydrolysis requires consider- 
ably less time than enzymatic leavage. However, the 
former method is frequently associated with extensive 
artifact formation [5]. Because conjugate formation is 
frequently incomplete, sufficient amounts of unconju- 
gated toxic subtances or their metabolites are still 
present in urine for extraction and identification. Be- 
cause highly polar metabolites frequently do not pass 
the gas chromatograph or may be prone to thermal 
decomposition, simple derivatization procedures are 
required [5]. 
In patients with anuria or acute renal failure, blood, 
plasma, or serum have to be used for the general 
unknown screening. The concentration range of a toxic 
substance in blood, plasma, or serum is typically lower 
compared to urine. However, the relative fraction of 
the unchanged toxic substance to its metabolites is 
frequently higher in blood compared to urine, which 
may facilitate the identification process. For a GC or 
GC-MS screening of volatiles, blood, plasma, or serum 
is generally the specimen of choice [6]. 
Extraction and Derivatization 
For practical reasons, liquid-liquid extraction and 
solid-phase xtraction are the most common extraction 
procedures in emergency toxicology. Liquid-liquid ex- 
traction frequently is preferred because it is more uni- 
versally applicable to many classes of toxic substances 
[5]. A variety of columns for solid-phase xtraction are 
commercially available. Because an ingested drug or 
toxicant may be acidic, neutral, or basic, extraction 
should be done at pHs of 3-4 and 8-9. For simplifica- 
tion both extracts may be unified. As a further step 
toward reducing the time for emergency analysis, the 
pH may be kept at about 8-9. Under this condition, 
most relevant drugs and toxicants and even acidic 
compounds with few exceptions (e.g., salicylic acid) 
will be extracted in sufficient quantities to be detected 
by the GC-MS procedure [3]. 
The most frequently used solvents for extraction are 
ethylacetate, diethylether, or mixtures of methylene 
chloride-isopropanol [4, 5]. The organic phase is evap- 
orated to dryness and the residue frequently is dis- 
solved in methanol [4, 5]. If the latter is used, one has 
to keep in mind the possibility of artifact formation. 
Due to the high polarity and thermal instability of 
many drugs, toxicants, and especially their metabo- 
lites, derivatization is advisable. Derivatization should 
preferrably be performed by using techniques that are 
Table 2. Information derived from analysis of different specimens for a general unknown 
screening inacute poisoning 
Specimen Information provided by GC-MS analysis 
Gastric lavage fluid/gastric ontent 
Urine 
Blood/plasma/serum 
Ingested drugs and toxicants that have not 
yet been absorbed 
Ingested drugs and toxicants that have 
undergone absorption, metabolism, and renal 
elimination 
Ingested drugs and toxicants that have 
undergone absorption and to some extent 
metabolism 
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fast and have a high yield of derivatives. For practical 
reasons, methylation that uses diazomethane or methyl 
iodide-potassium carbonate, acetylation with acetic 
anhydride, trifluoroacetylation with trifluoroacetic an- 
hydride, and pentafluoropropionylation with penta- 
fluoropropionic anhydride have some advantages over 
trimethylsilylation or use of organoboronic acid with 
respect o GC column bleeding and memory effects in 
the ion source of the mass spectrometer [3, 5, 18]. 
However, it has to be kept in mind that derivatization 
may be associated with considerable artifact forma- 
tion [3]. 
Gas Chromatography 
Capillary colurm~s are used as the standard in GC-MS 
screening procedures. Commercially available capil- 
lary columns allow adequate separation of tile com- 
plex mixtures typically present in urine extracts. A 
rapid temperature program is used to limit the dura- 
tion of the GC run, which typically ranges from 15-25 
rain. The maximum GC column temperature is typi- 
cally in the range of 300 °C. 
Mass-Spectral Techniques 
Due to the special requirements of a general unknown 
screening, electron impact (El) is still the most widely 
applied mode of ionization [3-5]. It has the advantage 
that it generates mass spectra with sufficient fragments 
to allow identification by a search of large EI mass 
spectra libraries. Other ionization techniques like posi- 
tive or negative chemical ionization, atmospheric pres- 
sure ionization, electrospray ionization, thermospray 
ionization, fast-atom bombardment, or the directly ex- 
posed probe in combination with tandem mass spec- 
trometry techniques may be useful additional options 
that provide complementary information, for example, 
on the molecular ion, to identify an unknown drug or 
toxicant [19-22]. 
Secondary fragment ion mass spectra may be ob- 
tained from molecular ions or [M + 1] ÷ ions by collision- 
induced dissociation. However, these secondary mass 
spectra may differ considerably from electron impact 
spectra, which renders a library search with an EI 
database difficult and limited in its reliability. There- 
fore, the standard ionization mode for a general un- 
known screening is still electron impact ionization. 
Identification of Drugs and Toxicants, 
their Metabolites, Derivatives, and 
Artifacts, Endogenous Substances, 
Food-Derived Substances, and 
Environmental Contaminants 
In urine extracts, unchanged drugs, toxicants, their 
metabolites, artifacts, and derivatives as well as en- 
dogenous ubstances and environmental contaminants 
may be present. Furthermore, substances derived from 
food or cigarette smoke like caffeine, theobromine, 
benzoic acid, hippuric acid, nicotine, and cotinine may 
be found [5]. Typical environmental contaminants in- 
clude phthalic esters, hydroxylated biphenyls, DDT 
and its metabolites, and pentachlorophenol [5]. Thera- 
peutic drugs frequently identified in urine extracts are 
lidocaine and catecholamines. Sulfur (S s) may be an 
artifact from therapeutic administration of high doses 
of N-acetylcysteine used in acetaminophen overdose. 
A urine extract typically contains abundant peaks of 
cholesterol, androstanol derivatives, fatty acids, bell- 
zoic acid, hippuric acid, phenols, and theobromine [4]. 
A problem in tile identification of an unknown 
agent may be coelution with other substances and/or  
peak tailing, which requires a background subtraction 
by all appropriate algorithm. Dependent on the sub- 
traction algorithm and the subtraction modalities cho- 
sen by the operator, tile resultant mass spectra may be 
subject to considerable alterations in fragment ion 
abundances. This may render identification of an un- 
known by a mass spectra library search rather difficult 
and prone to false interpretations. 
For identification of unknown agents, an automated 
mass spectra library comparison by computer is 
mandatory. However, large commercially available li- 
braries frequently do not contain all metabolites, arti- 
facts, and derivatives typically found in urine extracts. 
All updated data file especially for a general unknown 
GC-MS screening has been published by Pfleger, Mau- 
rer, and Weber [5]. 
In our experience, a general unknown screening of 
urine identifies previously unknown metabolites of a 
drug or toxicant in up to 10% of all cases of intoxica- 
tions with rare substances [4]. One reason is that drug 
or chemical overdose is associated with comparatively 
high concentrations of metabolites in the urine, which 
facilitates the identification of metabolites that are 
formed only in trace amounts under therapeutic dos- 
ing conditions or normal exposure. A large number of 
previously unknown metabolites, artifacts, and deriva- 
tives of drugs and toxicants detected by a general 
unknown screening in acute poisonings have been 
published. For previously unknown drug metabolites 
detected in drug overdose, further investigation gave 
evidence that all metabolites also were formed under a 
therapeutic dosing regimen (e.g., tiaprofenic acid, 
amantadine, tromantadine, dextromethorphan, chlor- 
phenoxamine, ajmaline, melperone, imipramine, pi- 
pamperone, chloroquine, propallylonal, and kavaine) 
[23-34]. 
The thermal challenge of the GC procedure may 
lead to artifact formation. Dehydration and formation 
of olefins is rather common [5]. In addition, the heat 
challenge may lead to ring formation and dehydration 
whenever a thermodynamically stable ring can be 
formed [5]. Artifact formation further may be due to 
N-oxidation of tertiary amines when diethylether is 
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used as a solvent, which may contain traces of perox- 
ide [5]. Similarly, sulfur in phenothiazine may be oxi- 
dized to sulfoxides [5]. The thermal challenge of GC 
may lead to decarboxylation of carboxylic acids [5]. 
N-oxides may undergo Cope elimination [5]. Derivati- 
zation by methylation or acetylation will lead to the 
formation of the corresponding methyl and acetyl 
derivatives. Derivatization with acetic anhydride is 
frequently associated with dehydration of alcohols [5]. 
Sometimes the use of methanol for reconstitution of 
an evaporated extract may lead to the formation of 
methylesters from carboxylic acid [5]. Furthermore, 
methanol may thermally decompose to traces of 
formaldehyde in the injection port of the gas chro- 
matographer, which then may undergo condensation 
with primary or secondary amines or induce ring clo- 
sure of 1,2-aminoalcohol groups, which are present, 
for example, in flecainide and most betablockers 
(e.g., metoprolol, see Figure 1) [35]. 
Furthermore, artifacts may be formed during hy- 
drochloric acid hydrolysis, which may lead to cleavage 
of an ether bridge in betablockers or alkanolamine 
antihistaminic drugs. Under hydrochloric acid hydrol- 
ysis, many 1,4-benzodiazepines are cleaved to form 
aminobenzophenone derivatives [5]. 
Identification of Toxic Substances 
A careful approach to background subtraction, decon- 
volution of overlapping peaks is a major prerequisite 
for identification of unknown agents by a library search. 
It requires thorough training and great experience in 
the field of mass spectrometry as well as clinical toxi- 
cology. In a first approach, physiological endogenous 
substances and substances not related to acute poison- 
ing have to be distinguished from exogenous toxic 
substances. Furthermore, food ingredients and typical 
environmental contaminants have to be identified. 
Then the drugs or toxicants that cause the acute poi- 
soning as well as their metabolites, derivatives, and 
artifacts have to be identified. A mass spectra library, 
which should contain a sufficient number of relevant 
reference spectra, is mandatory. Due to extensive 
metabolism or artifact formation, many drugs or toxi- 
cants can be detected only indirectly, for instance, by 
identification of their corresponding metabolites, arti- 
facts, or derivatives. In such cases, it must be kept in 
mind that an artifact, metabolite, or derivative some- 
times may be generated from different precursors. 
The interpretation process in a general unknown 
screening by GC-MS may become rather time-consum- 
ing if a drug is metabolized to a large number of 
metabolites as, for instance, propyphenazone, which 
forms about 20 metabolites [5]. Interpretation is further 
complicated if more than one drug is ingested, which 
is typically the case in about 46% of all suicidal cases 
of drug overdose [4]. 
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The results of the general unknown screening are 
required by the treating physician in emergency wards 
as rapidly as possible. A general unknown screening 
procedure takes an average of 2 11 [4]. Subsequent 
quantification of the identified toxic substance in blood, 
plasma, or serum is necessary to allow an estimation of 
the severity of the intoxication [1]. Quantification of an 
identified drug or toxicant should be performed with 
the most appropriate method of quantification, which 
may be high-performance liquid chromatography, gas 
chromatography, or, if available, immunological 
assays [1]. It need not necessarily be done by mass- 
spectral techniques. 
The mass spectra library should be updated with all 
metabolites, artifacts, and derivatives identified by the 
procedure. The database in this field is still growing at 
a rapid pace and many previously unknown metabo- 
lites and artifacts till have to be identified. 
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Examples for the Importance of a Gas 
Chromatography-Mass Spectrometry 
Screening Procedure for the Diagnosis of 
Acute Poisoning 
To exemplify the importance of a general unknown 
screening by using GC-MS and for a demonstration of
the practical problems that may be encountered in the 
identification and interpretation process, five case re- 
ports are presented. 
Case 1 (16-Year-Old Female) 
A 16-year-old female with a history of school problems 
was found comatose by her parents. The emergency 
ambulance staff found the patient in cardiovascular 
arrest. The parents uspected an intoxication with the 
calcium antagonist verapamil, which had been pre- 
scribed to the mother. Resuscitation was started by the 
emergency physician and his team with extreme doses 
of catecholamines. However, because fforts on the site 
were frustraneous, the patient was transported to the 
intensive care unit of our hospital with ongoing resus- 
citation in the emergency ambulance. In the intensive 
care unit, the patient's circulation could be stabilized. 
A general unknown screening ave evidence of the 
ingestion of the betablocker metoprolol and the 
monoamino xidase inhibitor moclobemide, but no 
veraparnil (see Figures 1 and 2). In addition to un- 
changed moclobemide and metoprolol, hydroxymeto- 
prolol and an artifact generated by reaction of 
formaldehyde with metoprolol could be identified [35]. 
Artifact formation was due to the use of methanol as 
the solvent for the extract. Trace amounts of formalde- 
hyde are formed by thermal decomposition f methanol 
during the GC procedure. 
In this case, the identification of metoprolol and 
moclobemide rather than verapamil in urine by tile 
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Figure 2. Part of the total ion chromatogram of the urine extract 
of case 1 (1 = heptadecanoic acid methyl ester, 2 = metoprolol, 
3 = acetic acid octadecyl ester, 4 = octadecenoic a id methyl 
ester, 5 = octadecanoic acid methyl ester, 6 = metoprolol artifact, 
7 = ethyl phenoxy benzene, 8 = docasane, 9 = moclobemide). 
therapy because verapamil poisoning refractory to 
standard treatment might have been by intravenous 
administration of high doses of calcium gluconate. 
This type of treatment occasio~lally has been reported 
to be successful in severe poisoning, although con- 
trolled studies are not available. However, high-dose 
calcium in calcium antagonist poisoning may be asso- 
ciated with the risk of a decrease in cerebral perfusion 
and cerebral ischemia. 
Circulation was stabilized further by high-dose in- 
fusion of catecholamines and high doses of glucagon. 
The patient recovered completely and was discharged 
without neuropsychological sequelae. In this case, the 
information provided by the parents about the proba- 
ble ingested drug was not correct. Tile results of the 
general unknown screening had important implica- 
tions for the further therapeutic management of the 
patient. 
Case 2 (47-Year-Old Male) 
A 47-year-old technician was found with drowsiness 
and a greyish discoloration of the skill in his laboratory 
by colleagues. He stated that, in a suicide attempt, he 
had ingested a chemical from a call, which was labeled 
"dimethylsulfone." The patient was admitted to the 
intensive care unit of tile hospital. The greyish discol- 
oration of the skin was due to 65c/c methemoglobine- 
mia in the blood, as determined by blood gas analysis. 
Therapy included adrninistration of ascorbic acid and 
toluidine blue to enhance the reduction of methe- 
moglobin to hemoglobin. However, very little is known 
about dimethylsulfone toxicity, especially in humans. 
From a theoretical point of view, it seems to be rather 
unlikely that dimethylsulfone is a significant oxidant 
to cause methemoglobinemia. 
A toxicological screening of urine extracts by GC-MS 
was performed. Dapsone, but no dimethylsulfone, 
could be identified (Figure 3). Dapsone is an antibiotic 
and immunomodulator used for treatment of leprosy 
and Duhring's disease. It is structurally related to 
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Electron impact mass pectrum of dapsone. 
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methemoglobinemia. The patient fully recovered and 
was discharged in complete health. 
In this case, GC-MS helped to identify the drug that 
caused the methemoglobinemia, although no hints or 
circumstances of the case had pointed to this type of 
chemical. The label on the can obviously had not been 
correct. 
Case 3 (76-Year-Old Female) 
A 76-year-old female was found comatose in her apart- 
ment by her neighbors. The reason for coma remained 
unclear. There were no empty drug containers, which 
might have suggested suicidal drug overdose. The 
patient was admitted to the ICU of the hospital. Respi- 
ratory insufficiency necessitated ventilator therapy. A 
toxicological screening performed with the patient's 
urine used immunological tests for benzodiazepines, 
barbiturates, opiates, tricyclic antidepressants, and 
acetaminophen. All toxicological tests were negative 
and poisoning seemed to be very unlikely. Cerebral 
bleeding, apoplexy, and basilar thrombosis were ruled 
out by cerebral computed tomography and digital sub- 
traction angiography. Laboratory tests gave no evi- 
dence for a metabolic dysregulation, which might have 
caused tile coma. The cerebrospinal fluid was normal. 
Because the patient remained in a coma for the next 
two days and an EEG showed burst suppression (inter- 
mittent isoelectric signals for 10 s), the toxicological 
screening was repeated, now via a GC-MS procedure. 
Glutethimide was identified (Figure 4). Plasma level 
data indicated severe glutethimide overdose. 
Glutethimide is a barbituratelike hypnotic that was 
used in Germany until the 1970s and then disappeared 
from the market. Obviously, this patient had stored 
containers with this drug in her apartment for a very 
long time and then used it to attempt suicide. 
Detoxification by repeated administration of acti- 
vated charcoal via a nasogastric tube and forced diure- 
sis was initiated. The patient's alertness gradually im- 
proved and she was discharged in complete health 
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Electron impact mass pectrum of glutethimide. 
This case demonstrates that a GC-MS screening is 
superior to a screening via immunological methods, 
which only cover a limited number of drugs. 
Case 4 (72-Year-Old Female) 
A 72-year-old female with no history of previous 
epilepsy was found with grand-mal seizures in her 
apartment by her neighbors. On admission to the hos- 
pital, the patient presented with a generalized epileptic 
state and coma. A neurological disease was assumed 
because no empty drug containers uggested drug 
overdose. A toxicological screening by immunological 
methods that covered barbiturates, opiates, tricyclic 
antidepressants, stimulants, acetaminophen, theophyl- 
line, and carbamazepine was negative. A thorough 
diagnostic procedure gave no evidence for neurologi- 
cal or metabolic disorders. Because manifestation of 
primary grand-mal seizures seemed to be very un- 
likely at an age of 72 years, the toxicological screening 
was repeated via a GC-MS procedure. Methaqualone 
and four of its metabolites were identified in urine 
(Figure 5). Methaqualone overdose is extremely rare 
because the drug disappeared from the market in 1980 
after it became subject o narcotic prescription law. The 
clinical characteristics of methaqualone overdose are 
hyperexcitability, seizures, and coma. 
This case again exemplifies the superiority of a 
GC-MS screening procedure over other methods, espe- 
cially immunological techniques. 
Case 5 (16-Month-Old Female) 
A 16-month-old infant was found cyanotic in her bed 
by her parents. Oil arrival of the emergency physician, 
the patient had cardiorespiratory arrest due to an un- 
known cause. Resuscitation was started. A general 
unknown screening via GC-MS yielded artifact A, but 
not B, which are typically formed after injection of 
thermally instable ergotamine into the GC-MS (Fig- 
ure 6). 
Further resuscitation efforts were frustraneous. Poi- 
soning of the child with ergotamine was assumed and 
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Major thermal decomposition products A and B 
were sent to our laboratory for confirmation as well as 
determination of ergotamine by HPLC. However, no 
ergotamine could be demonstrated in the blood extract 
at a detection limit of 0.6 ng /mL (toxic concentration 
range > 3 ng/mL).  Mass-spectral analysis was per- 
formed by using the direct exposed probe in the nega- 













Figure 7. Major fragment ions of ergotamine in the negative 
chemical ionization mode with methane. 
fragment ions (Figure 7) [36]. HPLC analysis with 
fluorescence detection was likewise negative (< 1 
ng /mL)  for ergotamine. However, the presence of arti- 
fact A but not B (Figure 6) could be confirmed by 
GC-MS. The most likely explanation for detection of A 
was that this artifact was formed by condensation of 
phenylalanine with proline, which are both physiologi- 
cally present in biological fluids (Figure 8). The diag- 
nosis in this case was not ergotamine intoxication, but 
most likely a sudden infant death syndrome, which is 
multifactorial in its causation according to present 
knowledge. 
If the original substance is too polar and thermally 
instable to pass the GC in the routine general un- 
known screening and only artifacts are formed, the 
interpretation process has to consider that sometimes 
different parent compounds may be the precursors of 
an artifact. In this case, no relevant ergotamine concen- 
trations could be detected via special mass-spectral 
techniques and HPLC. Artifact B could not be de- 
tected. The most likely source of artifact A was con- 
densation of phenylalanine with proline. 
Advantages and Disadvantages of a 
General Unknown Screening Via Gas 
Chromatography-Mass Spectrometry 
Although gas chromatography-mass spectrometry has 
become a rather old-fashioned technique, there are 
currently few alternatives that might be as efficient in 
identification of toxic substances in acute poisoning. 
However, GC-MS has some major disadvantages in a 
general unknown screening procedure: 
1. It requires extraction and sometimes conjugate 
cleavage prior to extraction. 
2. Only thermally stable drugs or toxicants can be 
detected in their undecomposed form by GC-MS. 
For thermally unstable compounds, derivatization 
procedures are required. 
3. The formation of artifacts from drugs, toxicants or 
their metabolites, and derivatives complicates the 
identification process. Daily routine work in this 
field indicates that many artifacts till remain to be 
identified [4, 5]. 
The standard ionization mode in a general un- 
known screening is electron impact ionization. Because 
reliable identification of toxic substances from an ex- 
0 
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Figure 8. Formation of A by condensation of phenylalanine 
with proline. 
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tract is required, a molecular ion or a [M +1] ~ ion with 
no fragment ions and the retention time are not spe- 
cific enough for a highly reliable identification of an 
unknown.  High reproducibil ity of a fragment ion mass 
spectrum is required to make identification by compar- 
ison of spectra with an EI l ibrary most reliable. The 
comparabil ity of mass spectra generated from molecu- 
lar ions by coll ision-induced dissociation with that of 
an El mass spectra library is lower than that of an EI 
spectrum. 
A step in the future might be the routine use of 
high-performance liquid chromatography-mass spec- 
trometry (HPLC-MS) with atmospheric pressure ion- 
ization or use of an electrospray for a general un- 
known screening. However, several problems have to 
be solved due to the specific needs of a general un- 
known screening: 
1. Universal HPLC columns or combinations of HPLC 
columns have to be used. 
2. The ionization technique has to be applicable uni- 
versally and has to provide sufficient sensitivity for 
a wide range of relevant substances. 
3. Furthermore, a fragment ion mass spectrum has to 
be generated, which should be as comparable as 
possible with an El spectrum to enable use of the 
huge databases of El mass spectra. 
4. The HPLC-MS screening procedure has to be tested 
under  routine condit ions in a large number  of poi- 
sonings with different classes of toxic substances. 
5. The mass spectra database has to be completed for 
drug and toxicant metabolites, artifacts, and deriva- 
tives detectable by HPLC-MS. 
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